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PRINCIPLES AND PRACTICE
ACTIVE MANAGEMENT 
IN SERIOUS GENETIC DISORDERS
by
J.A. Raeburn PHD, FRCPE 
Senior Lecturer in Human Genetics 
University of Edinburgh
.. et nous faisons maintenant la medicine d'une methode toute nouvelle" 
Le Misanthrope, Moliere, 1666
Twenty years ago we were taught to classify the 
cause of any medical condition into those that 
were 'genetic' and those that were 'acquired'. 
Subsequently the acquired group could be sub­
divided according to aetiology. Either directly or 
by implication we were told that genetic disorders 
were untreatable and that they were always rare, 
making up an insignificant proportion of medical 
practice. This article gives a personal view of the 
field of medical genetics and is based on two 
established facts, firstly that genetic diseases 
are now so frequent that every doctor should be 
conversant with basic genetic principles. Secondly 
many genetic conditions if not amenable to 
curative treatment, are at least responsive to 
careful management which can prolong and 
increase the quality of life. A t this stage we should 
emphasise one other aspect, which concerns the 
philosophy behind genetic counselling. Such 
counselling is not just the calculation of empiric 
or theoretical risks that a disease will recur, 
followed by telling the family and then leaving 
them to come to terms with unpleasant prob­
abilities. In genetic counselling the range of 
options open to different members of a family 
can be fully explained in the light of their risks. 
A t the same time counselling of a wider nature 
can be offered providing emotional support to 
many members of the family. By allowing indi­
viduals within a family to come to terms with 
the emotional aspects of an inherited condition, 
counselling, not necessarily provided by a genetic 
counsellor alone can be actively therapeutic.
Let us now select some severe disorders with 
a major genetic component and examine the 
therapeutic approaches available.
DOWN'S SYNDROME
In the United Kingdom there are at least 
19,000 patients with this chromosomal disorder, 
of whom around 30%  are in long-stay institutions. 
It is well known that the older pregnant woman 
has a higher risk of having a Down's baby, so that 
above the age of 40 the risk exceeds 2%. It is less 
frequently understood that over 70%  of babies 
with Down's syndrome are born to mothers who 
are aged less than 35, simply because the majority 
of pregnancies occur in younger women. The 
first implication of this figure is that 
amniocentesis, followed by selective termination 
of pregnancy, if offered to women over 35 will 
make only a small reduction in the birth incidence 
of Down's syndrome. At present there are no 
screening tests available to identify most of the 
younger women at risk of having babies with 
Down's syndrome. Since amniocentesis for the 
detection of chromosome abnormalities cannot 
be offered to all pregnant women, it follows that 
for the foreseeable future there will continue to 
be a large number of Down’s births. Therefore 
it is essential to pursue all possible approaches 
in treatment.
Management
Virtually all babies with Down's syndrome are 
identifiable at birth and this presents the
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advantage of early initiation of active 
management. This begins with a frank discussion 
with both parents, hopefully with the baby 
present, in which the features are explained briefly 
as well as what is known of the aetiology. Initially 
the parents may be so shocked that they say very 
little and appear to have no appropriate questions. 
However, it is important that they can form a 
good relationship with one doctor so that they can 
ask about whatever might worry them during the 
succeeding weeks or months. In the first few days 
it is often useful to suggest that the couple meet 
other parents, from similar families. This not only 
provides emotional help from someone who has 
met (and overcome) the same distress, but another 
parent can also encourage the couple to talk 
openly with the professionals about their fears 
and uncertainties. It is essential that all who con­
front a couple in this situation give honest 
answers to all their questions, even if the answer is 
that we do not know. Only in this way can a trust 
be built up with the professional services which is 
strong enough to augment active management.
The mainstay of management of most aspects 
of Down's syndrome in the first year is active 
stimulation. Thus the hypotonia is helped by 
simple physiotherapy whilst social development 
is aided by active stimulation of visual, auditory 
and tactile senses. In all aspects the parents and 
siblings can play a major role here, with appro­
priate professional guidance. A most successful 
recent innovation has been the appointment of 
educational home visitors who guide the parents 
and encourage them to teach a wide range of 
skills. The preliminary results of such 'active' 
management are yet to be evaluated fully but 
the signs are that the prognosis in Down's syn­
drome has been improved to such an extent that 
information in many textbooks, printed only a 
few years ago, is now out of date and excessively 
pessimistic.
Figu re  1: C lose co n tact w ith norm al ch ildren  is a 
fu rth er and m ost successful way to ensure 
that D o w n's infants are stim ulated. A  
norm al ch ild  can be m uch m ore sensitive to  
the short attention span o f a handicapped  
ch ild  than an adult can.
For the immediate future there are still more 
possibilities. Firstly we could consider the impact 
of the electronics industry on the habilitation 
methods available for Down's syndrome infants. 
There are a variety of electronic toys which are 
now sold for normal children which provide stim­
ulation for certain useful skills. I have already 
found that children with Down's syndrome can 
enjoy these games and can thereby be encouraged 
to develop some quite specific skills (eg. memory 
or hand-eye coordination). Within a short time 
simple computer systems, dedicated to the m ini­
misation of mental handicap will improve 
communication skills and thereby encourage 
better integration in the community. Some 
doctors are quite unaware of the recent rapid 
advances in educational psychology which have 
led to improved, more pragmatic teaching for the 
mentally handicapped. In Down's syndrome their 
excessive pessimism rapidly influences the parents 
who may either abandon all attempts to teach 
the baby simple skills (a course of action which 
would "handicap" the normal infant) or else 
may lose faith in all professionals, having realised 
the inaccuracy of early medical advice.
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Vision and Hearing in Down's Syndrome
There are several surveys which show that up to 
80%  of young children with Down's syndrome 
have visual or hearing handicaps which are easily 
amenable to treatment. In the case of hearing 
difficulty there are several causes, but transient 
or partial deafness often results from the narrower 
external auditory canal which, along with the 
susceptibility to upper respiratory infection, leads 
to middle-ear damage. It is easy to understand why 
a young child who is transiently deaf, who has 
visual handicap and whose parents have been told 
that the prognosis for speech and other communi­
cation skills is very poor, will fail to achieve.
Down's syndrome is certainly a genetic con­
dition which at present is incurable but there 
are surely numerous possibilities for active 
management. The principle to use in management 
is that the condition has many features, affecting 
a wide range of body functions. Only when we 
have treated all the treatable aspects fully will we 
truly discover the extent of the genetic handicap 
and the influence of new measures upon the 
developing Down's child's brain. When I counsel 
the parents of a Down's baby and they ask about 
the future I do not give them an unqualified and 
optimistic prognosis. Rather I tell them what we 
do now know while also mentioning all the 
positive actions that can be taken and that are 
known to minimise handicap.
INBORN ERRORS OF METABOLISM
Although individually very rare (the incidence 
of phenylketonuria is around 1 in 10,000 while 
for maple syrup urine disease it is 1 in 120,000) 
the inborn errors of metabolism collectively cause 
sufficient handicap for every paediatric unit to be 
provided with resources for diagnosis and manage­
ment. For over 20 years phenylketonuria (PKU) 
has been successfully managed by restriction of 
dietary phenylalanine. It has also been shown that 
the dietary regime can be relaxed in late childhood 
without apparent deterioration in cerebral 
function. Thus this genetic disorder can be 
managed so that the major handicap is preventable 
even if the genetic defect persists. There are other 
inborn errors in which this principle could be 
applied such as maple syrup urine disease in which 
restriction of the branched-chain amino acids 
(leucine, isoleucine and valine) can lead to immed­
iate clinical improvements. In this disease also, 
therapy with pharmacological doses of thiamine 
(up to 1000 mg per day) which acts with residual 
enzyme as a co-factor can also produce both 
clinical and biochemical improvement. Recent 
experience with PKU  has highlighted what may be 
a problem in many genetic diseases. Women who 
have been successfully treated for PKU  in infancy 
and childhood are now reaching the child-bearing 
ages and several pregnancies have now been 
described in the literature. The risk of their off­
spring also having PKU  is low, provided the father 
is unrelated to the mother and therefore unlikely 
to be a carrier of the disease. However, if the 
mother does not return to the special PKU  diet 
before the time of conception and throughout 
pregnancy, the foetus will be subjected to grossly 
elevated levels of phenylalanine and is at high risk 
of congenital defect, particularly mental handicap. 
Institution of a phenylalanine controlled diet 
prior to and throughout pregnancy can almost 
completely prevent such disasters. Whilst this 
highlights a growing problem, the PKU  experience 
illustrates how other inborn errors of metabolism 
may affect a foetus and opens up new approaches 
to preventive therapy.
Still more exciting is the possibility that some 
important inborn errors might be permanently 
controlled by the replacement of a missing enzyme 
with grafted tissue, possibly fibroblasts or bone 
marrow stem cells, from a histocompatible donor. 
Early evidence shows that in certain types of 
mucopolysaccaridosis, particularly Hurler's 
syndrome, such therapy can lead to prolonged 
biochemical improvements. The long-term clinical 
benefits are not yet known but, in theory at least, 
a bone marrow graft will be able to establish a 
source of monocytes from which macrophages 
in all parts of the body including the brain can be 
derived. Such treatment might be considered for 
many inborn errors of metabolism provided the 
enzyme is synthesised by monocytes or other 
donated cells.
CYSTIC FIBROSIS
Cystic fibrosis (CF) is the most frequent auto­
somal recessive condition in Caucasians with a 
birth incidence of approximately 1 in 2,000. 
This means that around 1 in 22 are carriers of the 
disorder, a proportion which has stimulated a
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search for precise methods for identifying the 
abnormal gene, whether in single or double dose. 
In Edinburgh, Drs. Jean Manson and David Brock 
have produced an antibody in guinea pigs to cystic 
fibrosis protein which shows early promise in 
detecting carriers of CF or pre-clinical cases. 
However, despite intensive research throughout 
the world the exact cause of CF remains elusive.
Our failure to know the biological basis for 
cystic fibrosis, however, need not mean that 
there is no treatment. Around 80% of CF patients 
have pancreatic insufficiency and for most of 
these malabsorption symptoms are improved 
adequately after regular therapy with appropriate 
enzymic dietary supplements. It may not be 
long before 'human' pancreatic enzymes are 
produced inexpensively in pure forms by bacteria 
as a result of genetic hybridisation manipulations.
All CF patients are at risk of respiratory in­
fection and this is the major cause of morbidity 
and mortality from the disease. During the past 
20 years, however, antibiotic therapy and active 
physiotherapy have brought about a fair improve­
ment both in the quality of life and in life 
expectancy, so that over 50% of CF children can 
now survive into adulthood. It is clear that there 
is a long way to go before the CF problem has 
been controlled, but some new regimes, which aim 
at individualising therapy for each patient based 
on the respiratory and immunological competence, 
are producing promising results.
CONGENITAL CNS MALFORMATIONS:
A RAPID GENETIC SOLUTION?
When I began genetic counselling almost ten 
years ago we saw many couples who had recently 
lost a baby in the neonatal period because of spina 
bifida or ananecephaly. We knew that the risk of 
further children being involved was moderately 
high, 1 chance in 20, or even higher if other 
children had been affected or there were previous 
spontaneous abortions. At that stage the mainstay 
of prevention was the parents' decision to have no 
further children. Shortly afterwards, in 1972, Dr. 
David Brock and Roger Sutcliffe showed that the 
amniotic fluid level of alphafetoprotein (AFP) 
was markedly elevated in pregnancies in which 
there was an open neural tube defect. This added 
a new approach for the prevention of CNS mal­
formations. Parents at high risk could be offered
an amniocentesis and, if the foetus was thereby 
shown to be affected, they could consider a 
termination of pregnancy. However, the (small) 
risk of amniocentesis was only justified if there 
was a high risk of neural tube defect, recognised 
because of a previous affected baby. Two or 
three years later David Brock found that a high 
proportion of pregnant women whose foetus was 
affected could be identified by the measurement 
of maternal serum levels of AFP at 16 weeks 
gestation, followed by selective amniocentesis 
in the 2 or 3% whose level was above a certain 
point. This identified the first foetus to be 
affected in many families.
During the past 18 months it has been shown 
that multivitamin or folic acid therapy taken for 
two months before and after conception may 
significantly reduce the risk of neural tube defect, 
even in 'high risk' families. The reason for this 
beneficial effect is far from clear but the data 
point to a simple dietary approach to the control 
of common and serious malformation syndromes. 
In the space of ten years we have passed from the 
dilemma of families with a high recurrence risk, 
via the ethical difficulties of selective terminations 
of pregnancy, towards realistic evidence of 
primary preventive therapy.
SUMMARY
This article has described briefly some aspects 
of four diseases or groups of diseases which are 
genetically determined in whole or in part. 
Collectively they account for morbidity in around 
1% of all conceptions and this fact belies the 
notion that genetic diseases are rare, even though 
there are many other inherited disorders which 
have not yet been considered. The main aim of 
this review has been to emphasise positive methods 
of management in four quite different situations. 
However, the principles of management are the 
same in all instances: if a direct cure of the patho­
logical process is not yet possible then the 
different aspects of the pathology can be tackled, 
separately and energetically, such as deafness due 
to infection in an infant with Down's syndrome 
or the respiratory infections in cystic fibrosis. 
Such simple measures can very greatly improve 
the quality of life and the prognosis notwith­
standing our lack of knowledge about the precise 
genetic defect. Furthermore, the possibility of
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direct therapy which is curative may not be far 
o ff for several genetic disorders. Anyone who 
seeks to manage a disorder with a hereditary 
element in the 1980s would do well to  take note 
of Hilaire Belloc's sarcasm:
There may be few 'cures' for genetic diseases 
but for the physicians with a therapeutic interest 
there is a challenge which may often be 
successfully tackled.
"Physicians of the utmost fame 
were called at once, but when they came 
they answered, as they took their fees, 
'There is no cure for this disease'."
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